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Upon activation, neutrophils release ﬁbers composed of chromatin and neutrophil proteins
termed neutrophil extracellular traps (NETs). NETs trap and kill microbes, activate dendritic
cells and T cells, and are implicated in autoimmune and vascular diseases. Given the
growing interest in the role of neutrophils in cancer immunoediting and the diverse function
of NETs, we searched for NETs release by tumor-associated neutrophils (TANs). Using
pediatric Ewing sarcoma (ES) as a model, we retrospectively examined histopathological
material from diagnostic biopsies of eight patients (mean ± SD age of 11.5 ± 4.7 years).
TANs were found in six patients and in two of those we identiﬁed NETs.These two patients
presented with metastatic disease and despite entering complete remission after intensive
chemotherapy had an early relapse. NETs were not identiﬁed in the diagnostic biopsies of
two patients with localized disease and two with metastatic disease.This study is the ﬁrst
to show thatTANs in ES are activated to make NETs, pointing to a possible role of NETs in
cancer.
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INTRODUCTION
Upon activation, neutrophils release neutrophil extracellular traps
(NETs), which are ﬁbers composed of chromatin and neutrophil
proteins. NETs are released via a novel form of cell death called
NETosis (Brinkmann and Zychlinsky, 2012). NETosis requires the
production of reactive oxygen species (ROS; Fuchs et al., 2007),
myeloperoxidase (MPO;Metzler et al., 2011) and on the transloca-
tion of neutrophil elastase (NE) from azurophilic granules to the
nucleus (Papayannopoulos et al., 2010). Eventually, neutrophils
release NETs that trap and kill microbes, activate dendritic cells
(DCs) and T cells, and are implicated in autoimmune and vascular
diseases(Brinkmann and Zychlinsky, 2012).
Wepostulated thatNETs also have a role in cancer. The immune
system can identify and destroy nascent tumor cells in a pro-
cess termed cancer immunosurveillance. However, the immune
system can also promote tumor progression. Together, these host-
protective and tumor-promoting actions of immunity are referred
to as cancer immunoediting (Kim et al., 2007). To our knowledge,
there are no data on the possible role of NETs in this process.
Ewing sarcoma (ES) is the second most common primary
bone cancer that afﬂicts adolescents and young adults. Although
advances in diagnosis, surgery, chemotherapy, and radiation have
substantially improved the survival rate of patients with localized
ES to nearly 70%, the long-term outcome for those with metastatic
or recurrent disease remains poor (Potratz et al., 2012). The impor-
tance of the immune system in anti-tumorigenic reactions against
ES cells was previously shown. Therapy-naive ES patients manifest
an inﬂammatory microenvironment with a high expression of
type 1-associated chemokines and inﬁltration of CD8+ T lym-
phocytes, expressing corresponding chemokine receptors. Patients
with higher numbers of tumor-inﬁltrating CD8+ T lymphocytes
demonstrated a signiﬁcant overall survival beneﬁt (Berghuis et al.,
2011). Potential targets for immune recognition speciﬁc to ES are
protein products of the gene fusion EWS-ETS (Meyer-Wentrup
et al., 2005) and other tumor-associated antigens like the ganglio-
side antigen GD2 (Kailayangiri et al., 2012). ES cells were also
shown to be sensitive to natural killer (NK) cells (Cho et al., 2010)
and to tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL), a member of the TNF superfamily with strong
anti-tumor activity and minimal toxicity to most normal cells and
tissues (Mitsiades et al., 2001). By contrast, several mechanisms of
immune escape are evident. Bone marrow T cells with a regula-
tory phenotype T(reg) were found at signiﬁcantly higher numbers
in patients with primary metastatic ES compared with local-
ized ES (Brinkrolf et al., 2009). In addition, complete or partial
absence of human leukocyte antigen (HLA) class I expression was
observed in 79%of ES tumors. Lungmetastases consistently lacked
HLA class I with sequential tumors, demonstrating a tendency
toward decreased expression with disease progression (Berghuis
et al., 2009).
Given the absence of data in the literature on the role of NETs in
cancer immunoediting, we used histopathological material from
diagnostic biopsies of pediatric ES patients to identify NETs in the
tumor bed.
www.frontiersin.org March 2013 | Volume 4 | Article 48 | 1
“ﬁmmu-04-00048” — 2013/3/5 — 11:29 — page 2 — #2
Berger-Achituv et al. NETs in Ewing sarcoma immunoediting
MATERIALS AND METHODS
PATIENTS
We aimed to examine histopathological material from diagnos-
tic biopsies of all ES patients (n = 14), who were treated in our
Pediatric Hemato-Oncology Department, Dana Children’s Hos-
pital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, between
July 2009 and July 2011. The histopathological material was taken
from diagnostic biopsies, before initiation of chemotherapy or
radiotherapy. All patients were previously healthy with no back-
ground systemic diseases or immunodeﬁciency and were free of
infection during removal of the biopsy samples. Three patients
were diagnosed elsewhere and therefore their histopathological
material was not available and in another three the remaining
material was insufﬁcient for NET analysis. Of the remaining eight
patients, six were males and two were females with a mean ± SD
age of 11.5 ± 4.7 years. Further data are summarized in Table 1.
The study was approved by the Institutional Review Board of Tel
Aviv Sourasky Medical Center, Tel Aviv, Israel.
TREATMENT PROTOCOL
Newly diagnosed non-metastatic ES patients received the Chil-
dren’s Oncology Group (COG) AEWS0031 regimen B (i.e.,
chemotherapy intensiﬁcation with alternate courses given every
2 weeks; Womer et al., 2012). ES patients with lung metastasis
at diagnosis were treated according to the European EURO-
E.W.I.N.G. 99 protocol R2 arm [i.e., consolidation with high-dose
chemotherapy (busulfan–melphalan) and peripheral blood stem
cell rescue; Ladenstein et al., 2010].
NETs ANALYSIS
Hematoxylin and eosin (HE) stained sections of the ES biopsies
were analyzed by a board-certiﬁed pathologist (Jonathan Ben-
Ezra) for the presence of tumor-associated neutrophils (TANs).
When TANs were identiﬁed, additional six 5-μm-thick sections
were cut from the same block and stained for the presence of NETs
as previously described (Brinkmann et al., 2004). In short, paraf-
ﬁn sections were hydrated before antigen retrieval by heating at
37◦C for 50 min with target retrieval solution, pH 9 (Dako, Ham-
burg,Germany). The sections were blockedwith 1%bovine serum
albumin (BSA), 3% donkey serum (Millipore GmbH, Schwal-
bach/Ts., Germany), 3% cold ﬁsh gelatin (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany), 0.05% Tween, and 0.025% Triton
for 30 min at room temperature, and incubated with primary anti-
bodies against CD99 (AbD Serotec, Düsseldorf, Germany) and
MPO (Dako, Hamburg, Germany) overnight at 4◦C in a humid
chamber. After washing, donkey anti-mouse Cy3 and donkey anti-
rabbit Alexa 488 (Dianova, Hamburg, Germany) were used as
secondary antibodies. The sections were also stained with the bis-
benzimid DNA dye “Hoechst” H33342 (Sigma-Aldrich Chemie
GmbH, Steinheim, Germany) and Draq5 DNA dye (New Eng-
land Biolabs GmbH, Frankfurt/M., Germany). Confocal images
were captured using Leica software (TCS-SP, Leica, Mannheim,
Germany).
RESULTS
Clinical and histopathological data on the eight ES patients that
were included in the study are provided in Table 1. NETs were
identiﬁed in the diagnostic biopsies of 2/8 patients: a 17-year-
old-male with a large ES mass of the left iliac bone, L5 vertebrae
involvement, and multiple lung metastases (patient 1) and a 15-
year-old-male with ES of the right proximal femur and suspected
lung metastases (patient 2). Both were treated with the EURO-
E.W.I.N.G. 99 protocol and after entering complete remission
underwent consolidation therapy with autologous stem cell trans-
plantation. Both had an early relapse, 12 and 18 months after stem
cell transplantation (22 and 27 months after diagnosis, respec-
tively). In comparison, NETs were not found in the biopsies of
four patients: a 3-year-old female and a 12-year-old male with
Table 1 | Clinical and histopathological data.
Pat.
No.
M/F At diagnosis Diagnostic biopsy Chemotherapy-
induced
necrosis*** (%)
Months from diagnosis
Age
(years)*
Primary disease
site
Lung/bone
metastasis
Neutrophils NETs Follow-up Relapse
1 M 17 Lt. Iliac bone yes yes yes 100**** 30 22
2 M 15 Rt. proximal femur yes yes yes 99 33 27
3 F 3 Lt. scapula no yes no 97–98 33 no
4 M 12 Lt. iliac bone no yes no 95**** 31 no
5 M 9 Lt. iliac bone yes yes no 99**** 23 no
6 M 8 L4 vertebrae yes yes no 100 13 no
7 F 16 Rt. distal ﬁbula no no NA** 100 43 no
8 M 13 Rt. metatarsal bones no no NA** 100 41 no
M/F, male/female; NA, not applicable.
*Mean age ± SD, 11.5 ± 4.7 years.
**Given that neutrophils were not identiﬁed in the tumor bed, further investigation for NETs was not performed.
***The percentage of chemotherapy-induced necrosis, which is used as a prognostic factor for patient outcome, is measured during deﬁnitive surgery (i.e., after six
courses of neo-adjuvant chemotherapy).
****Also received radiotherapy according to protocol.
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localized disease and 9-year-old and 8-year-old males with lung
metastases at diagnosis. These four patients are free of disease 33,
31, 23, and 13 months after diagnosis, respectively. In another
two patients with localized disease, TANs were not identiﬁed, thus
further investigation for NETs was not performed.
In the HE sections of both patients who demonstrated NETs
(Figures 1A,B,E,F), we observed small round blue cells charac-
teristic of ES. In patient 1, neutrophils invaded the ES cell mass;
whereas in patient 2, neutrophils were adjacent to the ES cells
inside, clearly deﬁnednecrotic tissue. Inbothpatients,weobserved
material that is suggestive of NETs (thick black arrows). Adja-
cent sections with immunoﬂuorescence staining demonstrated
the presence of NETs (Figures 1C,D,G,H). In both patients,
neutrophils were observed where MPO (green) is localized to
the granules, indicating non-activated cells (thick white arrows).
However, in many areas, MPO was localized to delobulated nuclei
(thin white arrows) and to extracellular DNA stained in red (white
arrowheads), attesting to the presence of NETs. In patient 1, NETs
were formed in close contact with ES cells, which are labeled with
CD99 antibodies (blue). Interestingly, CD99 appears degraded
in areas where neutrophils are present. In patient 2, NETs were
formed in the interface between ES cells and necrotic tissue. In the
necrotic areas of both patients, we observed extracellularDNA that
is not associated with MPO, indicating that these are not NETs.
DISCUSSION
This study is the ﬁrst to show that TANs in ES are activated to
make NETs and thus points to a possible role for NETs in cancer.
In the past, most of the research in the ﬁeld of cancer immu-
noediting was conﬁned to the role of T lymphocytes, NK cells,
macrophages, and DCs (Kim et al., 2007); less attention was given
to the role of neutrophils that are an essential effector cell of
the innate immune system, serving as the ﬁrst line of defense
against infectious microorganisms. Neutrophils have either pro-
or anti-tumor activity, depending on factors such as type of cancer
and cytokine proﬁle of the tumor microenvironment (Souto et al.,
2011). For example, transforming growth factor (TGF)-β within
the tumor induces a population of TANs with a pro-tumorigenic
phenotype. However, in the absence of TGF-β, TANs are cytotoxic
to tumor cells and express abundant pro-inﬂammatory cytokines
(Fridlender et al., 2009). Neutrophils can promote tumor growth
by secretion of matrix metalloproteinase (MMP)-9 that prevents
tumor cell apoptosis in the lungs (Acuff et al., 2006) and can pro-
mote tumor angiogenesis and neovascularization (Masson et al.,
2005). Nevertheless, neutrophils can also be cytotoxic to tumor
cells by producing several types of ROS (Lichtenstein, 1987; Dal-
legri et al., 1991). Notably, in a mouse model of breast cancer,
neutrophilswere shown to inhibitmetastatic seeding by generating
hydrogen peroxide (Granot et al., 2011). Neutrophils also produce
defensins, which can lyse cancer cells, recruit other immune cells,
such as DCs, and have anti-angiogenetic properties (Al-Benna
et al., 2011).
We speculate that NETs could have anti-tumorigenic effects, for
example by actual killing of tumor cells or activating the immune
system. Alternatively, NETs could have a pro-tumorigenic activity
by facilitating metastases. Indeed, the three-dimensional structure
of NETs may serve to physically capture tumor cells and prevent
FIGURE 1 | Neutrophil extrcellular traps (NETs) in Ewing sarcoma.The
histological HE stained sections of two patients in low (A,E) and high (B,F)
magniﬁcation suggest the presence of NETs (thick black arrows).
Immunoﬂuorescence staining for myeloperoxidase (MPO; green), CD99
(blue), and DNA (red) of sections adjacent to those shown in HE at low
(C,G) and high (D,H) magniﬁcation shows projections of a z-stack of
confocal sections 5-μm thick. Naïve Neutrophils are located where MPO is
in granules (thick white arrows). Neutrophils in the process of making NETs
are found where MPO is localized to delobulated nuclei (thin white arrows)
and NETs are located where MPO is colocalized with extracellular DNA
(white arrowheads; scale bars, 25 μm).
their dissemination to adjacent tissues. Several components of
NETs have been shown to be cytotoxic to tumor cells. MPO was
shown to kill B-16 melanoma cells and inhibit their growth in
mice after implantation (Odajima et al., 1996). It is of note that
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MPO deﬁcient patients may have an exceptionally high incidence
of cancer (7/14 patients, 50%; Lanza et al., 1988). NETs can kill
activated endothelial cell (Gupta et al., 2010), probably through
histones (Saffarzadeh et al., 2012), damaging tumor-feeding blood
vessels. NE secreted by TANs can cleave cyclin E (CCNE) to
its low molecular weight isoforms and thus promote their pre-
sentation to cytotoxic T lymphocytes (Mittendorf et al., 2012).
NETs modulate the link between innate and adaptive immune
responses by activating plasmacytoid DCs through toll-like recep-
tor 9 (TLR9), an intracellular receptor that recognizes DNA. This
NET-mediated activation is important in autoimmune diseases
like psoriasis (Skrzeczynska-Moncznik et al., 2012) and systemic
lupus erythematosus (Lande et al., 2011). We postulate that tumor
antigens caught on NET components could be displayed to DCs
and cause their activation. NETs also prime T cells by TCR signal-
ing that requires direct contact (Tillack et al., 2012). Alternatively,
NETs,whichharborpotent proteases, couldbepro-tumorigenic by
degradation of the extracellular matrix and promotion of metas-
tases. NETs may also form a barrier between cancer cells and
the immune system, thus assisting cancer cells to escape immune
recognition. The fact that both our patients withmetastatic disease
and NET formation relapsed may point to the pro-tumorigenic
mechanism of NETs.
Chemotherapy-induced necrosis is one of the most important
predictors of outcome in non-metastatic ES patients. Less than
90% necrosis after neo-adjuvant chemotherapy predicts a higher
relapse rate (Lin et al., 2007). Recently, van Maldegem et al. (2012)
suggested the need for additional biomarkers to predict outcome
and allow patient stratiﬁcation into different risk groups. Our
patients had a good histological response to chemotherapy includ-
ing the two patients who relapsed (Table 1); therefore, the presence
of NETs could possibly become an additional prognostic marker
in ES and other cancers.
Our study is limited by its retrospective design. We examined
biopsies that underwent standard histopathological processing
and were not necessarily handled with the same care required
for NETs preservation. Thus, we cannot rule out that NETs were
not found in other samples because they were damaged during
material handling or because only a small part of the tumor
was sampled. The study is also limited by its small sample size,
which precludes statistical analysis to ﬁrmly prove the clinical rel-
evance of NET formation in ES. A larger prospective cohort of
patients with diverse types of malignancies is advocated. How-
ever, we present these preliminary data due to the novelty of our
ﬁnding, supporting the notion that NETs have a role in cancer
immunoediting.
To conclude, this study provides the ﬁrst data on the release of
NETs by TANs in ES. Given that both patients with metastatic dis-
ease and NET formation relapsed may point to a pro-tumorigenic
mechanism of NETs and may constitute an important prognostic
marker in ES and in other cancers. This intriguing topic may have
a signiﬁcant contribution to our understanding of innate immune
responses against cancer and potentially lead to the development
of new therapeutic strategies in the battle against cancer.
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